Limits...
The diurnal and nocturnal effects of travoprost in normal-tension glaucoma.

Seibold LK, Kahook MY - Clin Ophthalmol (2014)

Bottom Line: TZ significantly reduced the mean diurnal and nocturnal IOP levels compared to baseline at all time points.The treatment effect on IOP endures for up to 3 days after the last dose.Treatment did not significantly improve OPP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, University of Colorado Eye Center, Aurora, CO, USA.

ABSTRACT

Purpose: To determine the diurnal and nocturnal effects of travoprost with sofZia(®) (Travatan Z(®) [TZ]) on intraocular pressure (IOP) and ocular perfusion pressure (OPP) in patients with normal-tension glaucoma (NTG).

Methods: Twenty-seven subjects with NTG were admitted to an inpatient sleep laboratory for three 24-hour sessions monitoring IOP, blood pressure (BP), and heart rate every 2 hours in the habitual position (diurnal period: upright; nocturnal period: supine). Baseline IOP and OPP levels were compared to those during active treatment with TZ and 3 days after stopping the medication. OPP was calculated as 2/3 [diastolic BP + 1/3 (systolic BP - diastolic BP)] - IOP.

Results: TZ significantly reduced the mean diurnal and nocturnal IOP levels compared to baseline at all time points. During treatment, mean IOP decreased from 17.1±3.4 to 14.7±3.0 mmHg during the diurnal period (P<0.01) and from 19.9±3.6 to 18.8±3.5 mmHg during the nocturnal period (P<0.01). Once treatment was discontinued, mean IOP remained at levels significantly less than baseline during both the diurnal (15.6±3.2 mmHg) and nocturnal (18.7±3.7 mmHg) periods. Mean OPP was not significantly changed with treatment during either period.

Conclusion: In this population of NTG patients, TZ significantly lowers IOP at all time points throughout the diurnal and nocturnal periods. The treatment effect on IOP endures for up to 3 days after the last dose. Treatment did not significantly improve OPP.

No MeSH data available.


Related in: MedlinePlus

Mean 24-hour profiles of intraocular pressure.Notes: Mean 24-hour profiles of intraocular pressure at baseline (circles), during travoprost with sofZia® treatment (squares), and after three missed doses (triangles). Error bars indicate the standard error of the mean.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4222622&req=5

f1-opth-8-2189: Mean 24-hour profiles of intraocular pressure.Notes: Mean 24-hour profiles of intraocular pressure at baseline (circles), during travoprost with sofZia® treatment (squares), and after three missed doses (triangles). Error bars indicate the standard error of the mean.

Mentions: During treatment with TZ, IOP was significantly reduced from 17.1±3.4 to 14.7±3.0 mmHg during the diurnal period and from 19.9±3.6 to 18.8±3.5 mmHg during the nocturnal period. Once the medication was discontinued for 3 days, mean IOP remained significantly reduced from baseline during both periods and statistically similar to levels during active treatment (P=0.2 diurnal period, P=0.45 nocturnal period). The mean IOP during the diurnal and nocturnal periods are displayed in Table 1. Figure 1 displays the IOP profiles from each 24-hour visit. Mean IOP during TZ therapy was significantly reduced at each time point during the diurnal period (upright) and, to a lesser degree, during the nocturnal period (supine). After three missed doses, the IOP levels at all time points during the diurnal period increased a minor amount, yet remained significantly less than baseline. Over the nocturnal period, there was no significant change in IOP reduction up to 84 hours after the last dose taken.


The diurnal and nocturnal effects of travoprost in normal-tension glaucoma.

Seibold LK, Kahook MY - Clin Ophthalmol (2014)

Mean 24-hour profiles of intraocular pressure.Notes: Mean 24-hour profiles of intraocular pressure at baseline (circles), during travoprost with sofZia® treatment (squares), and after three missed doses (triangles). Error bars indicate the standard error of the mean.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4222622&req=5

f1-opth-8-2189: Mean 24-hour profiles of intraocular pressure.Notes: Mean 24-hour profiles of intraocular pressure at baseline (circles), during travoprost with sofZia® treatment (squares), and after three missed doses (triangles). Error bars indicate the standard error of the mean.
Mentions: During treatment with TZ, IOP was significantly reduced from 17.1±3.4 to 14.7±3.0 mmHg during the diurnal period and from 19.9±3.6 to 18.8±3.5 mmHg during the nocturnal period. Once the medication was discontinued for 3 days, mean IOP remained significantly reduced from baseline during both periods and statistically similar to levels during active treatment (P=0.2 diurnal period, P=0.45 nocturnal period). The mean IOP during the diurnal and nocturnal periods are displayed in Table 1. Figure 1 displays the IOP profiles from each 24-hour visit. Mean IOP during TZ therapy was significantly reduced at each time point during the diurnal period (upright) and, to a lesser degree, during the nocturnal period (supine). After three missed doses, the IOP levels at all time points during the diurnal period increased a minor amount, yet remained significantly less than baseline. Over the nocturnal period, there was no significant change in IOP reduction up to 84 hours after the last dose taken.

Bottom Line: TZ significantly reduced the mean diurnal and nocturnal IOP levels compared to baseline at all time points.The treatment effect on IOP endures for up to 3 days after the last dose.Treatment did not significantly improve OPP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, University of Colorado Eye Center, Aurora, CO, USA.

ABSTRACT

Purpose: To determine the diurnal and nocturnal effects of travoprost with sofZia(®) (Travatan Z(®) [TZ]) on intraocular pressure (IOP) and ocular perfusion pressure (OPP) in patients with normal-tension glaucoma (NTG).

Methods: Twenty-seven subjects with NTG were admitted to an inpatient sleep laboratory for three 24-hour sessions monitoring IOP, blood pressure (BP), and heart rate every 2 hours in the habitual position (diurnal period: upright; nocturnal period: supine). Baseline IOP and OPP levels were compared to those during active treatment with TZ and 3 days after stopping the medication. OPP was calculated as 2/3 [diastolic BP + 1/3 (systolic BP - diastolic BP)] - IOP.

Results: TZ significantly reduced the mean diurnal and nocturnal IOP levels compared to baseline at all time points. During treatment, mean IOP decreased from 17.1±3.4 to 14.7±3.0 mmHg during the diurnal period (P<0.01) and from 19.9±3.6 to 18.8±3.5 mmHg during the nocturnal period (P<0.01). Once treatment was discontinued, mean IOP remained at levels significantly less than baseline during both the diurnal (15.6±3.2 mmHg) and nocturnal (18.7±3.7 mmHg) periods. Mean OPP was not significantly changed with treatment during either period.

Conclusion: In this population of NTG patients, TZ significantly lowers IOP at all time points throughout the diurnal and nocturnal periods. The treatment effect on IOP endures for up to 3 days after the last dose. Treatment did not significantly improve OPP.

No MeSH data available.


Related in: MedlinePlus